Apollo Management Holdings’s Calidi Biotherapeutics CLDI Stock Holding History

Apollo Management Holdings’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-65	Closed	-$249	–	93
2026 Q1	$249	Hold	65	–	–	﹤0.01%	86
2025 Q4	$1.22K	Hold	65	–	–	﹤0.01%	107
2025 Q3	$1.58K	Buy	+65	New	+$4.42K	﹤0.01%	52
2025 Q2	–	Sell	-65	Closed	-$7.08K	–	54
2025 Q1	$7.08K	Hold	65	–	–	﹤0.01%	48
2024 Q4	$14.4K	Hold	65	–	–	﹤0.01%	48
2024 Q3	$14.3K	Buy	+65	New	+$18.1K	﹤0.01%	42
2024 Q2	–	Sell	-65	Closed	-$70.6K	–	55
2024 Q1	$70.6K	Buy	+65	New	+$106K	﹤0.01%	53
2022 Q3	–	Sell	-619	Closed	-$11.8M	–	247
2022 Q2	$11.8M	Sell	619 -389	-39%	-$7.41M	0.08%	68
2022 Q1	$19.1M	Sell	1,008 -23	-2%	-$435K	0.09%	76
2021 Q4	$19.4M	Buy	+1,031	New	+$19.4M	0.08%	47

Other funds holding CLDI

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

IAA

Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return

RCI

RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BAM

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Apollo Management Holdings's CLDI Position: Q2 2026 in Review

Apollo Management Holdings sold out of Calidi Biotherapeutics (CLDI) in Q2 2026, closing a stake of 65 shares — an estimated $249 sold.

Apollo Management Holdings first reported a position in CLDI in Q4 2021 and held it in 10 quarters. The position peaked at $19.4M in Q4 2021. 22 funds tracked by Wall St. Rank hold CLDI as of Q2 2026.

Apollo Management Holdings reported no remaining Calidi Biotherapeutics position as of Q2 2026 after selling out during the quarter.
Apollo Management Holdings sold 65 Calidi Biotherapeutics shares in Q2 2026, an estimated $249.
Apollo Management Holdings first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 10 quarters.
Apollo Management Holdings's Calidi Biotherapeutics position peaked at $19.4M in Q4 2021.
22 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2026.

Based on Apollo Management Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.